Is pramlintide FDA-approved, and what does the research show?

What is pramlintide?

Pramlintide is a synthetic analog of human amylin, a hormone made by the beta cells of the pancreas, the same cells that make insulin ¹. An analog is the natural hormone with a few deliberate changes to its structure. The label describes pramlintide as a 37-amino-acid peptide ¹.

Amylin is released together with insulin when a person eats, and it helps control blood sugar after a meal ¹. In type 1 and type 2 diabetes, the beta cells release less of both hormones in response to food ¹.

Is pramlintide FDA-approved?

Yes, pramlintide is approved by FDA as Symlin ¹, and Drugs@FDA now lists every Symlin product as "Discontinued" ². FDA's Drugs@FDA record shows NDA 021332, approved March 16, 2005, with AstraZeneca AB as the sponsor ².

The label approves it "as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy" ¹, ⁵. Mealtime insulin is the insulin a person injects before eating to cover the rise in blood sugar from food. Adjunctive means pramlintide is added to that insulin, never used instead of it ¹.

That is the label's only use. It is not approved for weight loss, for people with diabetes who do not use mealtime insulin, or for anyone without diabetes ¹. The label says safety and effectiveness in children have not been established, and its patient-selection section lists "pediatric patients" among those who should not be considered for it ¹.

The Medication Guide calls it "an injectable prescription medicine" ¹. The label of record on Drugs@FDA is the December 2019 revision ⁵.

Whether Symlin is on the market today is less settled than its approval. Drugs@FDA lists all three Symlin presentations, a vial and two pen-injectors, with marketing status "Discontinued," in data updated November 6, 2026 ². FDA's National Drug Code directory, from the same data date, still lists the SymlinPen 60 and SymlinPen 120 under AstraZeneca with a marketing end date of January 31, 2027 ⁶. FDA recommends that a firm that has stopped making a product give, in most cases, its last lot's expiration date as the end date ⁷.

See the FDA status of every peptide, updated weekly.

How does pramlintide work?

The label describes three actions of amylin, found in nonclinical studies, meaning laboratory and animal work ¹. It slows gastric emptying, the rate at which food leaves the stomach for the small intestine, without changing how much of the food is absorbed ¹. It suppresses glucagon, a hormone that tells the liver to release glucose, so the liver puts out less sugar after a meal ¹. And it acts on the brain to reduce food intake ¹.

In people, the label says, pramlintide "slows gastric emptying, reduces the postprandial rise in plasma glucagon, and modulates satiety leading to decreased caloric intake" ¹. Postprandial means after a meal, and satiety is the sense of having eaten enough. In trials in people with type 1 and type 2 diabetes using mealtime insulin, it lowered glucose after meals, reduced swings in glucose, and reduced food intake ¹. The label says pramlintide alone does not cause hypoglycemia, but used with insulin it increases the risk of severe hypoglycemia ¹. Its half-life, the time for half of a dose to leave the blood, is about 48 minutes in healthy people ¹.

What does the research show?

The evidence for pramlintide in diabetes is at the top tier: FDA approval on randomized, double-blind, placebo-controlled trials, reported in the label ¹. Double-blind means neither participants nor investigators knew who received which treatment. HbA1c, or hemoglobin A1c, is the blood measure these trials use for glucose control over the preceding months ¹. Placebo-controlled means some participants received an inactive injection for comparison.

Studied in people with type 1 diabetes: three trials of 26 to 52 weeks, with the six-month results in the label ¹. Participants had a mean age of 40 years, 17 years of diabetes, and a mean body mass index, or BMI, of 25.9 ¹.

In the first trial, 243 patients on pramlintide lowered HbA1c by 0.58 percentage points against 0.25 in 237 on placebo ¹. The 0.34-point difference was statistically significant, meaning unlikely to be chance ¹. Weight fell 0.8 kilograms on pramlintide and rose 0.8 on placebo ¹. In the second, 148 patients on pramlintide lowered HbA1c by 0.24 points while 147 on placebo rose by 0.08, a significant difference of 0.32 ¹. Weight fell 1.6 kilograms against a gain of 0.4 ¹.

The third trial gave pramlintide three or four times a day to 164 and 161 patients, against 154 on placebo ¹. HbA1c fell 0.44 points in both pramlintide arms against 0.19 on placebo, a significant difference of 0.25 for each ¹. Weight fell 1.3 and 0.8 kilograms in the two pramlintide arms against a gain of 0.7 on placebo ¹.

A fourth type 1 trial reduced insulin at the start and let pramlintide be titrated, raised step by step, to what each patient tolerated ¹. In 148 patients on pramlintide against 147 on placebo, HbA1c fell by 0.47 and 0.49 points, with no difference between the groups ¹. The pramlintide group cut its mealtime insulin by 7.1 percent against 2.4 percent, and lost 1.33 kilograms where the placebo group gained 1.25 ¹.

Studied in people with type 2 diabetes: two trials, 26 and 52 weeks, in patients with an HbA1c above 8 percent on a fixed insulin dose ¹. Their mean BMI was about 33 ¹. The pramlintide arms of 166 and 126 patients lowered HbA1c by 0.66 and 0.36 points, against 0.32 and 0.06 in placebo arms of 161 and 123 ¹. The placebo-subtracted differences were 0.34 and 0.30 points, both statistically significant ¹. Weight fell by 1.4 and 1.6 kilograms on pramlintide, against gains of 0.3 and 0.1 kilograms on placebo ¹.

Pramlintide was then tested for obesity itself, in people not using insulin, in a series of phase 2 trials. A phase 2 trial is a mid-sized trial run before the large trials an approval needs.

Studied in people: a randomized, double-blind, placebo-controlled trial, 204 adults with obesity, with or without type 2 diabetes, mean BMI 37.8, 16 weeks, with no lifestyle program ³. Among those who completed the 16 weeks, pramlintide produced a placebo-corrected weight loss of 3.7 percent, or 3.6 kilograms ³. About 31 percent of pramlintide-treated participants lost at least 5 percent of their weight, against 2 percent on placebo ³. Withdrawals were 29 percent on pramlintide and 25 percent on placebo ³.

Studied in people: a randomized, double-blind, placebo-controlled trial, 411 adults with obesity, four months, with a lifestyle program ⁴. An eight-month single-blind extension followed, in which only one side knew the assignment ⁴. The trial gave pramlintide two or three times a day across six regimens ⁴. At month four the pramlintide arms had lost 3.8 to 6.1 kilograms against 2.8 on placebo, among 270 evaluable participants, those with data to analyze ⁴.

At month 12, among 146 evaluable participants, the low-dose three-times-daily and higher-dose twice-daily regimens showed placebo-corrected losses of 6.1 kilograms (5.6 percent) and 7.2 kilograms (6.8 percent) ⁴. In those two arms, 40 and 43 percent had lost at least 10 percent of their weight, against 12 percent on placebo ⁴. The placebo group had regained its initial loss by month 12 ⁴.

Studied in people: a 24-week randomized trial, placebo-controlled for pramlintide alone, 244 adults with obesity or overweight and without diabetes, mean BMI 37.7, with a lifestyle program ⁸. On its own, pramlintide produced a 3.7 percent weight loss against 2.2 percent on placebo ⁸. Combined with one of two older weight-loss pills, sibutramine or phentermine, the loss was about 11 percent ⁸. Heart rate and diastolic blood pressure rose on both combinations, and the combination arms were open-label, meaning everyone knew what they received ⁸.

Studied in people: a 24-week randomized, double-blind, active-controlled trial, 177 adults with obesity or overweight, of pramlintide with metreleptin ⁹. Metreleptin is a laboratory-made form of leptin, a hormone from fat tissue that signals the body's energy stores ⁹. A four-week lead-in, a run-in period before randomization, put everyone on pramlintide and a reduced-calorie diet ⁹. Those who had lost 2 to 8 percent were then randomized to metreleptin, pramlintide or both for 20 weeks ⁹. Among the 93 evaluable participants, weight fell 12.7 percent from enrollment on the combination, 8.4 percent on pramlintide alone and 8.2 percent on metreleptin alone ⁹.

A larger randomized, double-blind, placebo-controlled trial of the same pairing enrolled 636 adults with a BMI of 27 to 35 ¹⁰. It was dose-ranging, testing several doses, and posted its 28-week results by arm ¹⁰. In the evaluable population, weight fell 5.47 percent on pramlintide alone, 5.83 percent on metreleptin alone, 6.39 to 7.02 percent on the combinations and 2.01 percent on placebo ¹⁰. A follow-on trial of the combination, with 213 adults enrolled, was terminated in 2011 ¹¹. The registry gives the reason as "neutralizing activity to metreleptin in invitro assay in 2 participants" in the earlier study ¹¹.

None of the sources cited here reports a phase 3 trial of pramlintide for obesity. ClinicalTrials.gov lists a phase 2/3 trial of pramlintide added to semaglutide in people with obesity and prediabetes, withdrawn with no one enrolled, as of November 10, 2026 ¹². In these trials the placebo-corrected loss on pramlintide alone was about 1.5 to 7 percent ³, ⁴, ⁸, ¹⁰. None of the obesity trials ran beyond 12 months ³, ⁴, ⁸, ⁹, ¹⁰. Cagrilintide, another amylin analog, is a different molecule with its own page.

What are the side effects?

Nausea leads. In the label's pooled placebo-controlled trials in type 1 diabetes, 716 patients took pramlintide with insulin against 538 on placebo with insulin ¹. Nausea was reported by 48 percent against 17 percent, loss of appetite by 17 against 2, and vomiting by 11 against 7 ¹. "Inflicted injury," such as bruises, burns and fractures, was reported by 14 percent against 10 ¹. Joint pain was reported by 7 percent against 5, fatigue by 7 against 4, allergic reaction by 6 against 5 and dizziness by 5 against 4 ¹.

The pooled type 2 trials compared 292 patients on pramlintide with 284 on placebo ¹. There, nausea was 28 percent against 12, headache 13 against 7, loss of appetite 9 against 2 and vomiting 8 against 4 ¹. The label says nausea is highest at the start of treatment and falls with time in most patients ¹.

FDA's label carries a boxed warning at its head, the warning FDA sets apart in a box, in these words: "SYMLIN use with insulin increases the risk of severe hypoglycemia, particularly in patients with type 1 diabetes. When severe hypoglycemia occurs, it is seen within 3 hours following a SYMLIN injection. Serious injuries may occur if severe hypoglycemia occurs while operating a motor vehicle, heavy machinery, or while engaging in other high-risk activities. Appropriate patient selection, careful patient instruction, and insulin dose reduction are critical elements for reducing this risk" ¹, ⁵. In the trials, severe hypoglycemia meant an episode needing another person's help or treatment such as glucagon or intravenous glucose ¹.

In the type 1 trials that did not reduce insulin at the start, 16.8 percent of patients on pramlintide had such an episode in the first three months ¹. The placebo figure was 10.8 percent ¹. Episodes needing medical help ran 7.3 percent against 3.3 percent over the same months ¹. In the trial that reduced insulin at the start and titrated the dose, 13.5 percent on pramlintide had an episode in the first three months against 6.1 percent on placebo ¹. In the type 2 trials the figures were 8.2 percent against 2.1 percent for any severe episode, and 1.7 against 0.7 for episodes needing medical help ¹.

The label contraindicates pramlintide after a serious hypersensitivity reaction to it and in hypoglycemia unawareness, not feeling the warning signs of low blood sugar ¹. It also contraindicates it in confirmed gastroparesis, a condition in which the stomach empties too slowly ¹. Its patient-selection section names more people who should not be considered for it ¹. They include those with an HbA1c above 9 percent, recurrent severe hypoglycemia in the past six months, or a need for drugs that stimulate the gut ¹.

Its current label's warnings section 5.4, "Never Mix SYMLIN and Insulin," says "SYMLIN and insulin must always be administered as separate injections and should never be mixed" ⁵. It can delay the absorption of pills taken with it, and it is not recommended with drugs that alter gut motility ¹. Reports after approval add injection-site reactions and pancreatitis, inflammation of the pancreas ¹. The current label carries the warning "Never Share a SymlinPen Between Patients" ⁵.

In two of the obesity trials nausea was the most common adverse event, mild and passing in one, mostly mild to moderate in the other ³, ⁴. Over four months in the 411-person trial it was reported by 9 to 29 percent on pramlintide against 2 percent on placebo ⁴. With metreleptin, injection-site events and nausea led ⁹.

In sport

Pramlintide is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency, and amylin analogs are not a listed class ¹³. The list names no amylin analog in any of its sections ¹³.

Section S0 of the list reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times" ¹³. Drugs@FDA lists every Symlin product as "Discontinued" ².

What JumpstartMD offers

JumpstartMD does not prescribe pramlintide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.